See some of our highlights and milestones below.

  • 1960 – The Quokka Story

    Muscular Dystrophy Western Australia (MDWA) and Perron Institute, originally the Australian Neuromuscular Research Institute (ANRI) – owe their origins to the humble Rottnest Island quokka and Emeritus Professor Byron Kakulas’ discovery he could regenerate their muscle.

  • 1965 – Inclusion Body Myositis identified as a clinical identity

    Inclusion body myositis [IBM] was distinguished from polymyositis in a biopsy examined by Byron Kakulas in 1965. Fred Samaha went on to clearly define the entity which was later elucidated via electron microscopy by Sam Chou.

  • 1967 – Emeritus Professor Byron Kakulas AO

    Emeritus Professor Byron Kakulas, then Professor of Neuropathology at the University of Western Australia, in partnership with a group of parents whose children suffered from muscular dystrophy took the bold decision to establish the Muscular Dystrophy Association of Western Australia, now Muscular Dystrophy Western Australia.

  • 1971 – Major International Congress on Muscle Diseases

    Perth hosted a major international congress on muscle diseases where the idea of establishing a neuromuscular research institute in Perth was born.

  • 1978 – Location established at SCGH

    The WA Government indicated that it was prepared to make space available in the old Sir Charles Gairdner Hospital building at the Queen Elizabeth II Medical Centre in Nedlands.

  • 1982 – Official establishment of ANRI

    In 1982, the Australian Neuromuscular Research Institute was established with Professor Kakulas as its Foundation Director.

  • 1993 – Perron Institute contributed to the discovery of the SOD1 MND gene

    Researchers at the Perron Institute (then the Australian Neuromuscular Research Institute) played a significant part in discovering the first gene (SOD1) associated with MND, in collaboration with researchers in the United States, Canada and Europe.

  • 2014 – The Institute is renamed WANRI

    The institute was renamed to the Western Australian Neuroscience Research Institute, paying homage to its WA origins.

  • 2016 – First Duchenne drug receives accelerated approval from the US FDA

    A ground-breaking drug developed by Professors Steve Wilton AO and Sue Fletcher AO to treat Duchenne muscular dystrophy received accelerated approval from the US Food and Drug Administration (FDA). The first of three drugs approved by the US FDA.

  • 2017 – The Institute takes on the Perron name

    In 2017, we proudly became the Perron Institute for Neurological and Translational Science in honour of Mr Stan Perron AC and his family’s long-standing support.

  • 2019 – Second drug for Duchenne achieves US FDA accelerated approval

    Developed by Professors Sue Fletcher AO and Steve Wilton AO at the Perron Institute via The University of Western Australia, Vyondys 53 is the second exon skipping therapy for Duchenne muscular dystrophy to receive accelerated approval by the United States Food and Drug Administration.

  • 2021 – Third drug for Duchenne achieves US FDA accelerated approval

    The third treatment for Duchenne muscular dystrophy developed by our WA research team led by Professors Steve Wilton AO and Sue Fletcher AO, received accelerated approval by the United States Food and Drug Administration (US FDA).